In the first quarter, Green Thumb reported revenue of $300.2 million, an increase of 7.4% year over year, and earnings per share of $0.07, an increase of 75% from the same quarter a year ago. The company has $289.9 million in total debt, but $344.5 million in cash and cash equivalents.

The company has done a good job of building up its brands, which helps insulate it from the price compression affecting the industry. The company’s brands include RYTHM, Dogwalkers, Incredibles, Beboe, &Shine, Doctor Solomon’s, and Good Green.

Why I like Tilray Brands

Tilray, based in Canada, has an international presence, with operations in Canada, Europe, and the U.S. beverage market. Changes in U.S. regulations would allow Tilray to expand in the U.S., and a more favorable tax environment here could boost its revenue and earnings.

Tilray already has a toehold in the U.S. Following strategic acquisitions — including an expansive portfolio of craft beer brands from Anheuser-Busch and its acquisition of BrewDog — Tilray has shielded itself from pure cannabis volatility. This infrastructure gives it an instant, legally compliant distribution network into U.S. retail and bars, which can be easily leveraged for THC- and CBD-infused beverages when federal laws shift, as well as give it a base to eventually operate cannabis sales in the U.S. The company already said it is looking into a pilot Center for Medicare and Medicaid Innovation program that would let it supply hemp-derived medical cannabis to patients through specific healthcare groups and cancer clinics.

The company is coming off a record third quarter, in which revenue grew 11% year over year to $206.7 million, including 73% growth in international sales.

Tilray also trimmed its total debt by 6% to $549 million. Management reconfirmed positive full-year adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance of $62 million to $72 million, representing growth of 13% to 31%, proving that its underlying operations are scaling effectively.

Tilray is a hidden gem

The stock, because it doesn’t yet sell cannabis in the U.S., is being overlooked compared to other large cannabis retailers. However, due to its growth in international sales and its marketing experience in the U.S. through its beverage sales, it has the wherewithal to pounce on new opportunities in the U.S.

The stock is priced right, with a price-to-sales ratio of 0.541, lower than Trulieve, Curaleaf, and Green Thumb Industries.

Green Thumb may still be the safer bet because it has a longer history of profitability, but Tilray offers several overlooked advantages and greater growth potential.

Should you buy stock in Green Thumb Industries right now?

Before you buy stock inGreen Thumb Industries, consider this:

The Motley FoolStock Advisoranalyst team just identified what they believe are the 10 best stocksfor investors to buy now… andGreen Thumb Industrieswasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider whenNetflixmade this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,you’d have $443,191!* Or when Nvidiamade this list on April 15, 2005… if you invested $1,000 at the time of our recommendation,you’d have $1,258,838!*

That performance is why people listen. With a track record ofbeating the S&P 500 by 4x,Stock Advisoroffers a distinct advantage. Don’t miss the latest top 10 list, available withStock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of June 7, 2026.

James Halley has no position in any of the stocks mentioned. The Motley Fool recommends Green Thumb Industries and Tilray Brands. The Motley Fool has a disclosure policy.

The Single Biggest Cannabis Catalyst in Years Is Rapidly Approaching: 2 Marijuana Stocks to Buy Now was originally published by The Motley Fool